Caution/Monitor.piroxicamMonitor Closely (1)piroxicam increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.pitolisantMonitor Closely (1)arformoterol and pitolisant both increase QTc interval. Use Caution/Monitor.ponesimodMonitor Closely (1)arformoterol and ponesimod both increase QTc interval. Use Caution/Monitor.posaconazoleMonitor Closely (1)arformoterol and posaconazole both increase QTc interval. Use Caution/Monitor.potassium acid phosphateMonitor Closely (1)potassium acid phosphate increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.potassium chlorideMonitor Closely (1)potassium chloride increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.potassium citrateMonitor Closely (1)potassium citrate increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.primaquineMonitor Closely (1)arformoterol and primaquine both increase QTc interval. Use Caution/Monitor.primidoneMonitor Closely (1)primidone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.procainamideMonitor Closely (1)arformoterol and procainamide both increase QTc interval. Use Caution/Monitor.procarbazineMonitor Closely (1)procarbazine increases effects of arformoterol by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.prochlorperazineMonitor Closely (1)prochlorperazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.promethazineMonitor Closely (1)promethazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.propafenoneMonitor Closely (1)arformoterol and propafenone both increase QTc interval. Use Caution/Monitor.propranololMonitor Closely (2)propranolol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. propranolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.propylhexedrineMonitor Closely (2)arformoterol and propylhexedrine both decrease sedation. Use Caution/Monitor. arformoterol and propylhexedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.protriptylineMonitor Closely (2)arformoterol and protriptyline both increase QTc interval. Use Caution/Monitor. protriptyline increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)protriptyline, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.pseudoephedrineMonitor Closely (1)arformoterol and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.quazepamMonitor Closely (1)quazepam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.quetiapineMonitor Closely (2)quetiapine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. arformoterol and quetiapine both increase QTc interval. Use Caution/Monitor.quinidineMonitor Closely (1)arformoterol and quinidine both increase QTc interval. Use Caution/Monitor.quinineMonitor Closely (1)arformoterol and quinine both increase QTc interval. Use Caution/Monitor.ranolazineMonitor Closely (1)arformoterol and ranolazine both increase QTc interval. Use Caution/Monitor.ribociclibMonitor Closely (1)ribociclib increases toxicity of arformoterol by QTc interval. Use Caution/Monitor.rilpivirineMonitor Closely (1)arformoterol and rilpivirine both increase QTc interval. Use Caution/Monitor.risperidoneMonitor Closely (2)risperidone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. arformoterol and risperidone both increase QTc interval. Use Caution/Monitor.romidepsinMonitor Closely (1)arformoterol and romidepsin both increase QTc interval. Use Caution/Monitor.sacubitril/valsartanMonitor Closely (1)sacubitril/valsartan increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sageMinor (1)sage increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Minor/Significance Unknown.salicylates (non-asa)Monitor Closely (1)salicylates (non-asa) increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.salmeterolMonitor Closely (3)arformoterol and salmeterol both decrease serum potassium. Use Caution/Monitor. arformoterol and salmeterol both decrease sedation. Use Caution/Monitor. arformoterol and salmeterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.salsalateMonitor Closely (1)salsalate increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.saquinavirMonitor Closely (1)arformoterol and saquinavir both increase QTc interval. Use Caution/Monitor.scullcapMonitor Closely (1)scullcap increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.secobarbitalMonitor Closely (1)secobarbital increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.selpercatinibMonitor Closely (1)selpercatinib increases toxicity of arformoterol by QTc interval. Use Caution/Monitor.serdexmethylphenidate/dexmethylphenidateMonitor Closely (1)arformoterol and serdexmethylphenidate/dexmethylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.sertralineMonitor Closely (1)arformoterol and sertraline both increase QTc interval. Use Caution/Monitor.sevofluraneMonitor Closely (1)arformoterol and sevoflurane both increase QTc interval. Use Caution/Monitor.shepherd's purseMonitor Closely (1)shepherd's purse increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.siponimodMonitor Closely (1)arformoterol and siponimod both increase QTc interval. Use Caution/Monitor.sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycolMonitor Closely (1)arformoterol and sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycol both decrease serum potassium. Modify Therapy/Monitor Closely.solifenacinMonitor Closely (1)arformoterol and solifenacin both increase QTc interval. Use Caution/Monitor.solriamfetolMonitor Closely (1)arformoterol and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.sorafenibMonitor Closely (1)sorafenib and arformoterol both increase QTc interval. Use Caution/Monitor.sotalolMonitor Closely (3)sotalol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. arformoterol and sotalol both increase QTc interval. Use Caution/Monitor. sotalol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.spironolactoneMonitor Closely (1)spironolactone increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.succinylcholineMonitor Closely (1)succinylcholine increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sufentanilMonitor Closely (1)sufentanil increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.sulfasalazineMonitor Closely (1)sulfasalazine increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sulindacMonitor Closely (1)sulindac increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sunitinibMonitor Closely (1)arformoterol and sunitinib both increase QTc interval. Use Caution/Monitor.tacrolimusMonitor Closely (1)arformoterol and tacrolimus both increase QTc interval. Use Caution/Monitor.tapentadolMonitor Closely (1)tapentadol increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.telavancinMonitor Closely (1)arformoterol and telavancin both increase QTc interval. Use Caution/Monitor.temazepamMonitor Closely (1)temazepam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.terbutalineMonitor Closely (3)arformoterol and terbutaline both decrease serum potassium. Use Caution/Monitor. arformoterol and terbutaline both decrease sedation. Use Caution/Monitor. arformoterol and terbutaline both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.tetrabenazineMonitor Closely (1)arformoterol and tetrabenazine both increase QTc interval. Use Caution/Monitor.thioridazineContraindicated (1)arformoterol and thioridazine both increase QTc interval. Contraindicated.Monitor Closely (1)thioridazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.thiothixeneMonitor Closely (1)thiothixene increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.timololMonitor Closely (2)timolol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor. timolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.tolfenamic acidMonitor Closely (1)tolfenamic acid increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.tolmetinMonitor Closely (1)tolmetin increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.tolvaptanMonitor Closely (1)tolvaptan increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.topiramateMonitor Closely (1)topiramate increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.toremifeneMonitor Closely (1)arformoterol and toremifene both increase QTc interval. Use Caution/Monitor.torsemideMonitor Closely (1)arformoterol and torsemide both decrease serum potassium. Use Caution/Monitor.Minor (1)arformoterol, torsemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.tramadolMonitor Closely (1)tramadol increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.tranylcypromineSerious - Use Alternative (1)tranylcypromine increases effects of arformoterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.trazodoneMonitor Closely (2)trazodone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. arformoterol and trazodone both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)trazodone, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.triamtereneMonitor Closely (1)triamterene increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.triazolamMonitor Closely (1)triazolam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.triclabendazoleMonitor Closely (1)arformoterol and triclabendazole both increase QTc interval. Use Caution/Monitor.triclofosMonitor Closely (1)triclofos increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazineMonitor Closely (1)trifluoperazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trimipramineMonitor Closely (2)arformoterol and trimipramine both increase QTc interval. Use Caution/Monitor. trimipramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trimipramine, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.triprolidineMonitor Closely (1)triprolidine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.triptorelinMonitor Closely (1)triptorelin increases toxicity of arformoterol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.umeclidinium bromide/vilanterol inhaledSerious - Use Alternative (1)arformoterol increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.valbenazineMonitor Closely (1)valbenazine and arformoterol both increase QTc interval. Use Caution/Monitor.vandetanibMonitor Closely (1)arformoterol and vandetanib both increase QTc interval. Use Caution/Monitor.vardenafilMonitor Closely (1)arformoterol and vardenafil both increase QTc interval. Use Caution/Monitor.vemurafenibMonitor Closely (1)arformoterol and vemurafenib both increase QTc interval. Use Caution/Monitor.vilanterol/fluticasone furoate inhaledSerious - Use Alternative (1)arformoterol increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.voclosporinMonitor Closely (1)voclosporin, arformoterol. Either increases effects of the other by QTc interval. Use Caution/Monitor.voriconazoleMonitor Closely (1)arformoterol and voriconazole both increase QTc interval. Use Caution/Monitor.vorinostatMonitor Closely (1)arformoterol and vorinostat both increase QTc interval. Use Caution/Monitor.xylometazolineMonitor Closely (2)arformoterol and xylometazoline both decrease sedation. Use Caution/Monitor. arformoterol and xylometazoline both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.yohimbineMonitor Closely (2)arformoterol and yohimbine both decrease sedation. Use Caution/Monitor. arformoterol and yohimbine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.ziconotideMonitor Closely (1)ziconotide increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ziprasidoneMonitor Closely (2)ziprasidone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. arformoterol and ziprasidone both increase QTc interval. Use Caution/Monitor. 1-10% Back pain (6%) Chest pain (7%) Diarrhea (6%) Dyspnea (4%) Flu syndrome (3%) Leg cramps (4%) Lung disorder (2%) Pain (8%) Peripheral edema (3%) Rash (4%) Sinusitis (5%) Contraindications Hypersensitivity to arformoterol or formoterol, or any ingredients Treatment of asthma without a concomitant long-term asthma control medication, such as an inhaled corticosteroid Cautions Use only if not adequately controlled by asthma controller medications Use only for shortest duration of time Immediate hypersensitivity reactions may occur after administration of arformoterol inhalation solution as demonstrated by cases of anaphylactic reaction, urticaria, angioedema, rash and bronchospasm Beta-agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects; the decrease in serum potassium is usually transient, not requiring supplementation Beta-agonist medications may produce transient hyperglycemia in some patients; clinically significant and dose-related changes in serum potassium and blood glucose were infrequent during clinical trials with long-term administration of arformoterol inhalation Solution at recommended dose Use caution in patients with coexisting conditions, including convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to sympathomimetic amines; doses of the related beta2-agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis As with other inhaled beta2-agonists, arformoterol inhalation solution can produce paradoxical bronchospasm that may be life-threatening; if paradoxical bronchospasm occurs, arformoterol inhalation solution should be discontinued immediately and alternative therapy instituted Fatalities reported in association with excessive use of inhaled sympathomimetic drugs; as with other inhaled beta2-adrenergic drugs, arformoterol inhalation solution should not be used more often, at higher doses than recommended, or in conjunction with other medications containing long-acting beta2-agonists Serious Asthma-Related Events Safety and efficacy of Inhalation Solution in patients with asthma not established Inhalation Solution is not indicated for treatment of asthma Use of long-acting beta2-adrenergic agonists (LABA) as monotherapy [without inhaled corticosteroids (ICS)] for asthma is associated with an increased risk of asthma-related death Available data from controlled clinical trials suggest that use of LABA as monotherapy increases risk of asthma-related hospitalization in pediatric and adolescent patients These findings are considered a class effect